Global Viral Inactivation Market Size Insights Forecasts to 2033

• The Global Viral Inactivation Market Size was Valued at USD  653.8 Million in 2023
• The Market Size is Growing at a CAGR of 11.35% from 2023 to 2033
• The Worldwide Viral Inactivation Market Size is Expected to Reach USD 1915.2 Million by 2033
• Asia Pacific is Expected to Grow the fastest during the forecast period.

The Global Viral Inactivation Market Size is Anticipated to Exceed USD 1915.2 Million by 2033, Growing at a CAGR of 11.35% from 2023 to 2033.   

Market Overview

The technique of making viruses non-infectious by deleting their genetic material or structure prevents the virus from proliferating and spreading to new people this is known as viral inactivation. Primarily, this process is carried out to improve security and prevent viruses in the sample from infecting the intended product. The infection might be there in the finished product, but it cannot be active. To protect them from viral activity, the food and blood plasma companies use a variety of inactivation procedures. In the pharmaceutical industry, viral inactivation lowers the risk of viral contamination, safeguarding biological products made from human or animal cells, including recombinant proteins, blood products, and vaccinations. Increases in the prevalence of chronic diseases including cancer, autoimmune conditions, and other diseases worldwide as well as rising healthcare costs are the main drivers driving the growth of the viral inactivation market. Viral inactivation is one of the critical safety measures that are required due to the growing market for biologics and biosimilars, which are driven by their effectiveness in treating a range of disorders.  

Report Coverage

This research report categorizes the global viral inactivation market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global viral inactivation market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global viral inactivation market.

Driving Factors

The increasing focus on research and development in biological fields, the rapid expansion of the biotechnology and pharmaceutical sectors, and the increasing prevalence of chronic diseases are the primary factors driving the global viral inactivation market. The global viral inactivation market is also being driven by growing government funding for the pharmaceutical and biopharmaceutical sectors, a rise in investments in the life sciences business, and a rise in drug approvals and releases. Improved biopharmaceutical treatments are required to combat the growing incidence of chronic and fatal diseases like hepatitis, HIV, and cancer.

Restraining Factors

High levels of competition and the high costs of manufacturing biosimilar medicines are predicted to restrict the market's ability to create demands. The market for viral inactivation will face increasing difficulties due to a lack of skilled workers.

Market Segmentation

The global viral inactivation market share is classified into product, application, and end user.

• The kits & reagents segment is expected to hold the largest share of the global viral inactivation market during the forecast period.   

Based on the product, the global viral inactivation market is divided into kits & reagents, systems & accessories, and services. Among these, the kits & reagents segment is expected to hold the largest share of the global viral inactivation market during the forecast period. This is demonstrated by the growth of biopharmaceutical and biotechnological businesses across the world. The segment for kits and reagents has benefited from businesses' growing development efforts and new product introductions.   

For instance, in 2023, the efficient viral inactivation, Croda Pharma launched Virodex TXR-1 and TXR-2. Drug development is a result of increased R&D spending, and this is what is propelling market expansion.

• The vaccines and therapeutics segment is expected to hold the largest share of the global viral inactivation market during the forecast period.   

Based on the application, the global viral inactivation market is divided into vaccines and therapeutics, stem cell products, blood and blood products, tissue/ tissue products, and cellular and gene therapy. Among these, the vaccines and therapeutics segment is expected to hold the largest share of the global viral inactivation market during the forecast period. Growing investments in R&D uses, including stem cell and gene therapy, are a major factor in the market growth. The need for inactivated vaccines has surged due to the rising prevalence of cancer and other chronic diseases, which is further anticipated to drive market growth.    

• The pharmaceutical and biotechnology companies segment is expected to hold the largest share of the global viral inactivation market during the forecast period.   

Based on the end user, the global viral inactivation market is divided into pharmaceutical and biotechnology companies, CROs, academic and research institutes, and others. Among these, the pharmaceutical and biotechnology companies’ segment is expected to hold the largest share of the global viral inactivation market during the forecast period. The growth of biopharmaceutical and pharmaceutical businesses contributed to funding the search for alternative treatments, leading to a rise in the production of new medications. To guarantee the safety of the product, these companies use a range of processes, including low pH, solvent detergent, and bioreactors.      

Regional Segment Analysis of the Global Viral Inactivation Market Size

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global viral inactivation market over the predicted timeframe.

North America is anticipated to hold the largest share of the global viral inactivation market over the predicted timeframe. The North American viral inactivation Market is being driven by the explosive rise of biotechnology and pharmaceuticals. The US has the largest market share in North America in terms of revenue. The main causes of this are improved hospital systems, advanced machinery and technology, and growing healthcare costs. The North America Viral Inactivation Market is driven by the growing prevalence of chronic diseases and a growing focus on life sciences research and development.

Asia Pacific is expected to grow at the fastest pace in the global viral inactivation market during the forecast period. The biopharmaceutical sector in the Asia-Pacific region is growing quickly due to higher investments in biotechnology and healthcare infrastructure. Improved viral inactivation technologies which drive market growth in nations like China and India are required for this growth.

Europe is anticipated to hold a significant share of the global viral inactivation market over the predicted timeframe. The market has grown in Europe's advanced healthcare system, well-developed infrastructure, and extensive R&D. Better techniques for viral inactivation can be developed by depending on research conducted by the German Center for Infection Research on the eco-immunological aspects related to viral infections.  

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global viral inactivation market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Charles River Laboratories, Inc.
• Clean Cells
• Merck KGaA
• Mettler Toledo
• Parker Hannifin Corp
• Rad Source Technologies Inc
• Sartorius AG
• Texcell SA
• Vironova AB
• Danaher Corporation
• Thermo Fisher Scientific
• Bio-Rad Laboratories
• GE Healthcare
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In June 2023, Texcell SA announced the launch of a testing center in North America. It is anticipated that this action will assist the business in improving the viral safety and biotherapeutic and medical device clearance processes.
• In March 2022, Thermo Fisher Scientific announced a non-hazardous InhibiSURE Viral Inactivation Medium formula. a novel viral transport medium that stabilizes viral RNA for use in in vitro diagnostic testing techniques and facilitates the rapid transfer and inactivation of the SARS-CoV-2 virus.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the global viral inactivation market based on the below-mentioned segments: 

Global Viral Inactivation Market, By Product

• Kits and Reagents
• Systems & Accessories
• Services

Global Viral Inactivation Market, By Application

• Vaccines and Therapeutics
• Stem Cell Products
• Blood and Blood Products
• Tissue/ Tissue Products
• Cellular and Gene Therapy

Global Viral Inactivation Market, By End User

• Pharmaceutical and Biotechnology Companies
• CROs
• Academic and Research Institutes
• Others

Global Viral Inactivation Market, By Regional

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa